0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global KRAS Inhibitor Market Research Report 2024
Published Date: September 2024
|
Report Code: QYRE-Auto-39N18158
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global KRAS Inhibitor Market Research Report 2024
BUY CHAPTERS

Global KRAS Inhibitor Market Research Report 2024

Code: QYRE-Auto-39N18158
Report
September 2024
Pages:78
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

KRAS Inhibitor Market Size

The global KRAS Inhibitor market was valued at US$ 121 million in 2023 and is anticipated to reach US$ 216 million by 2030, witnessing a CAGR of 8.3% during the forecast period 2024-2030.

KRAS Inhibitor Market

KRAS Inhibitor Market

KRAS inhibitors are a class of targeted cancer therapies designed to block the activity of the KRAS protein, a common driver of cancer, particularly in pancreatic, colorectal, and lung cancers. KRAS mutations are notoriously difficult to target because the protein has a smooth surface with few pockets for drug binding. However, recent advances have led to the development of specific inhibitors, such as sotorasib and adagrasib, which target the G12C mutation in KRAS, a mutation present in a subset of cancers. These inhibitors work by irreversibly binding to the mutant KRAS protein, preventing it from signaling the uncontrolled cell growth that leads to cancer. While these drugs have shown promise, they are not universally effective, and resistance often develops, leading to ongoing research to improve their efficacy and expand their use to other KRAS mutations.
North American market for KRAS Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for KRAS Inhibitor is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of KRAS Inhibitor include Amgen, Boehringer Ingelheim, BridgeBio Pharma, Erasca, Innovent Biologics, Incyte, Mirati Therapeutics, Novartis, Jemincare, Cardiff Oncology, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for KRAS Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding KRAS Inhibitor.
The KRAS Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global KRAS Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the KRAS Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of KRAS Inhibitor Market Report

Report Metric Details
Report Name KRAS Inhibitor Market
Accounted market size in 2023 US$ 121 million
Forecasted market size in 2030 US$ 216 million
CAGR 8.3%
Base Year 2023
Forecasted years 2024 - 2030
Segment by Type
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Amgen, Boehringer Ingelheim, BridgeBio Pharma, Erasca, Innovent Biologics, Incyte, Mirati Therapeutics, Novartis, Jemincare, Cardiff Oncology
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of KRAS Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of KRAS Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is KRAS Inhibitor Market growing?

Ans: The KRAS Inhibitor Market witnessing a CAGR of 8.3% during the forecast period 2024-2030.

What is the KRAS Inhibitor Market size in 2030?

Ans: The KRAS Inhibitor Market size in 2030 will be US$ 216 million.

Who are the main players in the KRAS Inhibitor Market report?

Ans: The main players in the KRAS Inhibitor Market are Amgen, Boehringer Ingelheim, BridgeBio Pharma, Erasca, Innovent Biologics, Incyte, Mirati Therapeutics, Novartis, Jemincare, Cardiff Oncology

What are the Application segmentation covered in the KRAS Inhibitor Market report?

Ans: The Applications covered in the KRAS Inhibitor Market report are Clinic Laboratories, Cancer Diagnostic Centres, Hospitals, Others

What are the Type segmentation covered in the KRAS Inhibitor Market report?

Ans: The Types covered in the KRAS Inhibitor Market report are Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Others

Recommended Reports

Cancer Inhibitor Drugs

Cancer Targeted Therapy

Cancer Treatment Markets

1 KRAS Inhibitor Market Overview
1.1 Product Definition
1.2 KRAS Inhibitor by Type
1.2.1 Global KRAS Inhibitor Market Value Comparison by Type (2024-2030)
1.2.2 Lung Cancer
1.2.3 Pancreatic Cancer
1.2.4 Colorectal Cancer
1.2.5 Others
1.3 KRAS Inhibitor by Application
1.3.1 Global KRAS Inhibitor Market Value by Application (2024-2030)
1.3.2 Clinic Laboratories
1.3.3 Cancer Diagnostic Centres
1.3.4 Hospitals
1.3.5 Others
1.4 Global KRAS Inhibitor Market Size Estimates and Forecasts
1.4.1 Global KRAS Inhibitor Revenue 2019-2030
1.4.2 Global KRAS Inhibitor Sales 2019-2030
1.4.3 Global KRAS Inhibitor Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 KRAS Inhibitor Market Competition by Manufacturers
2.1 Global KRAS Inhibitor Sales Market Share by Manufacturers (2019-2024)
2.2 Global KRAS Inhibitor Revenue Market Share by Manufacturers (2019-2024)
2.3 Global KRAS Inhibitor Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of KRAS Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of KRAS Inhibitor, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of KRAS Inhibitor, Product Type & Application
2.7 Global Key Manufacturers of KRAS Inhibitor, Date of Enter into This Industry
2.8 Global KRAS Inhibitor Market Competitive Situation and Trends
2.8.1 Global KRAS Inhibitor Market Concentration Rate
2.8.2 The Global 5 and 10 Largest KRAS Inhibitor Players Market Share by Revenue
2.8.3 Global KRAS Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global KRAS Inhibitor Market Scenario by Region
3.1 Global KRAS Inhibitor Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global KRAS Inhibitor Sales by Region: 2019-2030
3.2.1 Global KRAS Inhibitor Sales by Region: 2019-2024
3.2.2 Global KRAS Inhibitor Sales by Region: 2025-2030
3.3 Global KRAS Inhibitor Revenue by Region: 2019-2030
3.3.1 Global KRAS Inhibitor Revenue by Region: 2019-2024
3.3.2 Global KRAS Inhibitor Revenue by Region: 2025-2030
3.4 North America KRAS Inhibitor Market Facts & Figures by Country
3.4.1 North America KRAS Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America KRAS Inhibitor Sales by Country (2019-2030)
3.4.3 North America KRAS Inhibitor Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe KRAS Inhibitor Market Facts & Figures by Country
3.5.1 Europe KRAS Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe KRAS Inhibitor Sales by Country (2019-2030)
3.5.3 Europe KRAS Inhibitor Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific KRAS Inhibitor Market Facts & Figures by Region
3.6.1 Asia Pacific KRAS Inhibitor Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific KRAS Inhibitor Sales by Region (2019-2030)
3.6.3 Asia Pacific KRAS Inhibitor Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America KRAS Inhibitor Market Facts & Figures by Country
3.7.1 Latin America KRAS Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America KRAS Inhibitor Sales by Country (2019-2030)
3.7.3 Latin America KRAS Inhibitor Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa KRAS Inhibitor Market Facts & Figures by Country
3.8.1 Middle East and Africa KRAS Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa KRAS Inhibitor Sales by Country (2019-2030)
3.8.3 Middle East and Africa KRAS Inhibitor Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global KRAS Inhibitor Sales by Type (2019-2030)
4.1.1 Global KRAS Inhibitor Sales by Type (2019-2024)
4.1.2 Global KRAS Inhibitor Sales by Type (2025-2030)
4.1.3 Global KRAS Inhibitor Sales Market Share by Type (2019-2030)
4.2 Global KRAS Inhibitor Revenue by Type (2019-2030)
4.2.1 Global KRAS Inhibitor Revenue by Type (2019-2024)
4.2.2 Global KRAS Inhibitor Revenue by Type (2025-2030)
4.2.3 Global KRAS Inhibitor Revenue Market Share by Type (2019-2030)
4.3 Global KRAS Inhibitor Price by Type (2019-2030)
5 Segment by Application
5.1 Global KRAS Inhibitor Sales by Application (2019-2030)
5.1.1 Global KRAS Inhibitor Sales by Application (2019-2024)
5.1.2 Global KRAS Inhibitor Sales by Application (2025-2030)
5.1.3 Global KRAS Inhibitor Sales Market Share by Application (2019-2030)
5.2 Global KRAS Inhibitor Revenue by Application (2019-2030)
5.2.1 Global KRAS Inhibitor Revenue by Application (2019-2024)
5.2.2 Global KRAS Inhibitor Revenue by Application (2025-2030)
5.2.3 Global KRAS Inhibitor Revenue Market Share by Application (2019-2030)
5.3 Global KRAS Inhibitor Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Company Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen KRAS Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen KRAS Inhibitor Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Boehringer Ingelheim
6.2.1 Boehringer Ingelheim Company Information
6.2.2 Boehringer Ingelheim Description and Business Overview
6.2.3 Boehringer Ingelheim KRAS Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Boehringer Ingelheim KRAS Inhibitor Product Portfolio
6.2.5 Boehringer Ingelheim Recent Developments/Updates
6.3 BridgeBio Pharma
6.3.1 BridgeBio Pharma Company Information
6.3.2 BridgeBio Pharma Description and Business Overview
6.3.3 BridgeBio Pharma KRAS Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.3.4 BridgeBio Pharma KRAS Inhibitor Product Portfolio
6.3.5 BridgeBio Pharma Recent Developments/Updates
6.4 Erasca
6.4.1 Erasca Company Information
6.4.2 Erasca Description and Business Overview
6.4.3 Erasca KRAS Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Erasca KRAS Inhibitor Product Portfolio
6.4.5 Erasca Recent Developments/Updates
6.5 Innovent Biologics
6.5.1 Innovent Biologics Company Information
6.5.2 Innovent Biologics Description and Business Overview
6.5.3 Innovent Biologics KRAS Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Innovent Biologics KRAS Inhibitor Product Portfolio
6.5.5 Innovent Biologics Recent Developments/Updates
6.6 Incyte
6.6.1 Incyte Company Information
6.6.2 Incyte Description and Business Overview
6.6.3 Incyte KRAS Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Incyte KRAS Inhibitor Product Portfolio
6.6.5 Incyte Recent Developments/Updates
6.7 Mirati Therapeutics
6.7.1 Mirati Therapeutics Company Information
6.7.2 Mirati Therapeutics Description and Business Overview
6.7.3 Mirati Therapeutics KRAS Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Mirati Therapeutics KRAS Inhibitor Product Portfolio
6.7.5 Mirati Therapeutics Recent Developments/Updates
6.8 Novartis
6.8.1 Novartis Company Information
6.8.2 Novartis Description and Business Overview
6.8.3 Novartis KRAS Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Novartis KRAS Inhibitor Product Portfolio
6.8.5 Novartis Recent Developments/Updates
6.9 Jemincare
6.9.1 Jemincare Company Information
6.9.2 Jemincare Description and Business Overview
6.9.3 Jemincare KRAS Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Jemincare KRAS Inhibitor Product Portfolio
6.9.5 Jemincare Recent Developments/Updates
6.10 Cardiff Oncology
6.10.1 Cardiff Oncology Company Information
6.10.2 Cardiff Oncology Description and Business Overview
6.10.3 Cardiff Oncology KRAS Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Cardiff Oncology KRAS Inhibitor Product Portfolio
6.10.5 Cardiff Oncology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 KRAS Inhibitor Industry Chain Analysis
7.2 KRAS Inhibitor Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 KRAS Inhibitor Production Mode & Process
7.4 KRAS Inhibitor Sales and Marketing
7.4.1 KRAS Inhibitor Sales Channels
7.4.2 KRAS Inhibitor Distributors
7.5 KRAS Inhibitor Customers
8 KRAS Inhibitor Market Dynamics
8.1 KRAS Inhibitor Industry Trends
8.2 KRAS Inhibitor Market Drivers
8.3 KRAS Inhibitor Market Challenges
8.4 KRAS Inhibitor Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global KRAS Inhibitor Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global KRAS Inhibitor Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global KRAS Inhibitor Market Competitive Situation by Manufacturers in 2023
 Table 4. Global KRAS Inhibitor Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global KRAS Inhibitor Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global KRAS Inhibitor Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global KRAS Inhibitor Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market KRAS Inhibitor Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of KRAS Inhibitor, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of KRAS Inhibitor, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of KRAS Inhibitor, Product Type & Application
 Table 12. Global Key Manufacturers of KRAS Inhibitor, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global KRAS Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in KRAS Inhibitor as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global KRAS Inhibitor Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global KRAS Inhibitor Sales by Region (2019-2024) & (K Units)
 Table 18. Global KRAS Inhibitor Sales Market Share by Region (2019-2024)
 Table 19. Global KRAS Inhibitor Sales by Region (2025-2030) & (K Units)
 Table 20. Global KRAS Inhibitor Sales Market Share by Region (2025-2030)
 Table 21. Global KRAS Inhibitor Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global KRAS Inhibitor Revenue Market Share by Region (2019-2024)
 Table 23. Global KRAS Inhibitor Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global KRAS Inhibitor Revenue Market Share by Region (2025-2030)
 Table 25. North America KRAS Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America KRAS Inhibitor Sales by Country (2019-2024) & (K Units)
 Table 27. North America KRAS Inhibitor Sales by Country (2025-2030) & (K Units)
 Table 28. North America KRAS Inhibitor Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America KRAS Inhibitor Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe KRAS Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe KRAS Inhibitor Sales by Country (2019-2024) & (K Units)
 Table 32. Europe KRAS Inhibitor Sales by Country (2025-2030) & (K Units)
 Table 33. Europe KRAS Inhibitor Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe KRAS Inhibitor Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific KRAS Inhibitor Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific KRAS Inhibitor Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific KRAS Inhibitor Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific KRAS Inhibitor Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific KRAS Inhibitor Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America KRAS Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America KRAS Inhibitor Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America KRAS Inhibitor Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America KRAS Inhibitor Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America KRAS Inhibitor Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa KRAS Inhibitor Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa KRAS Inhibitor Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa KRAS Inhibitor Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa KRAS Inhibitor Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa KRAS Inhibitor Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global KRAS Inhibitor Sales (K Units) by Type (2019-2024)
 Table 51. Global KRAS Inhibitor Sales (K Units) by Type (2025-2030)
 Table 52. Global KRAS Inhibitor Sales Market Share by Type (2019-2024)
 Table 53. Global KRAS Inhibitor Sales Market Share by Type (2025-2030)
 Table 54. Global KRAS Inhibitor Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global KRAS Inhibitor Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global KRAS Inhibitor Revenue Market Share by Type (2019-2024)
 Table 57. Global KRAS Inhibitor Revenue Market Share by Type (2025-2030)
 Table 58. Global KRAS Inhibitor Price (US$/Unit) by Type (2019-2024)
 Table 59. Global KRAS Inhibitor Price (US$/Unit) by Type (2025-2030)
 Table 60. Global KRAS Inhibitor Sales (K Units) by Application (2019-2024)
 Table 61. Global KRAS Inhibitor Sales (K Units) by Application (2025-2030)
 Table 62. Global KRAS Inhibitor Sales Market Share by Application (2019-2024)
 Table 63. Global KRAS Inhibitor Sales Market Share by Application (2025-2030)
 Table 64. Global KRAS Inhibitor Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global KRAS Inhibitor Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global KRAS Inhibitor Revenue Market Share by Application (2019-2024)
 Table 67. Global KRAS Inhibitor Revenue Market Share by Application (2025-2030)
 Table 68. Global KRAS Inhibitor Price (US$/Unit) by Application (2019-2024)
 Table 69. Global KRAS Inhibitor Price (US$/Unit) by Application (2025-2030)
 Table 70. Amgen Company Information
 Table 71. Amgen Description and Business Overview
 Table 72. Amgen KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. Amgen KRAS Inhibitor Product
 Table 74. Amgen Recent Developments/Updates
 Table 75. Boehringer Ingelheim Company Information
 Table 76. Boehringer Ingelheim Description and Business Overview
 Table 77. Boehringer Ingelheim KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Boehringer Ingelheim KRAS Inhibitor Product
 Table 79. Boehringer Ingelheim Recent Developments/Updates
 Table 80. BridgeBio Pharma Company Information
 Table 81. BridgeBio Pharma Description and Business Overview
 Table 82. BridgeBio Pharma KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. BridgeBio Pharma KRAS Inhibitor Product
 Table 84. BridgeBio Pharma Recent Developments/Updates
 Table 85. Erasca Company Information
 Table 86. Erasca Description and Business Overview
 Table 87. Erasca KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 88. Erasca KRAS Inhibitor Product
 Table 89. Erasca Recent Developments/Updates
 Table 90. Innovent Biologics Company Information
 Table 91. Innovent Biologics Description and Business Overview
 Table 92. Innovent Biologics KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 93. Innovent Biologics KRAS Inhibitor Product
 Table 94. Innovent Biologics Recent Developments/Updates
 Table 95. Incyte Company Information
 Table 96. Incyte Description and Business Overview
 Table 97. Incyte KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 98. Incyte KRAS Inhibitor Product
 Table 99. Incyte Recent Developments/Updates
 Table 100. Mirati Therapeutics Company Information
 Table 101. Mirati Therapeutics Description and Business Overview
 Table 102. Mirati Therapeutics KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 103. Mirati Therapeutics KRAS Inhibitor Product
 Table 104. Mirati Therapeutics Recent Developments/Updates
 Table 105. Novartis Company Information
 Table 106. Novartis Description and Business Overview
 Table 107. Novartis KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 108. Novartis KRAS Inhibitor Product
 Table 109. Novartis Recent Developments/Updates
 Table 110. Jemincare Company Information
 Table 111. Jemincare Description and Business Overview
 Table 112. Jemincare KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 113. Jemincare KRAS Inhibitor Product
 Table 114. Jemincare Recent Developments/Updates
 Table 115. Cardiff Oncology Company Information
 Table 116. Cardiff Oncology Description and Business Overview
 Table 117. Cardiff Oncology KRAS Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 118. Cardiff Oncology KRAS Inhibitor Product
 Table 119. Cardiff Oncology Recent Developments/Updates
 Table 120. Key Raw Materials Lists
 Table 121. Raw Materials Key Suppliers Lists
 Table 122. KRAS Inhibitor Distributors List
 Table 123. KRAS Inhibitor Customers List
 Table 124. KRAS Inhibitor Market Trends
 Table 125. KRAS Inhibitor Market Drivers
 Table 126. KRAS Inhibitor Market Challenges
 Table 127. KRAS Inhibitor Market Restraints
 Table 128. Research Programs/Design for This Report
 Table 129. Key Data Information from Secondary Sources
 Table 130. Key Data Information from Primary Sources
 Table 131. Authors List of This Report


List of Figures
 Figure 1. Product Picture of KRAS Inhibitor
 Figure 2. Global KRAS Inhibitor Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global KRAS Inhibitor Market Share by Type: 2023 & 2030
 Figure 4. Lung Cancer Product Picture
 Figure 5. Pancreatic Cancer Product Picture
 Figure 6. Colorectal Cancer Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global KRAS Inhibitor Market Value by Application (2024-2030) & (US$ Million)
 Figure 9. Global KRAS Inhibitor Market Share by Application: 2023 & 2030
 Figure 10. Clinic Laboratories
 Figure 11. Cancer Diagnostic Centres
 Figure 12. Hospitals
 Figure 13. Others
 Figure 14. Global KRAS Inhibitor Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 15. Global KRAS Inhibitor Market Size (2019-2030) & (US$ Million)
 Figure 16. Global KRAS Inhibitor Sales (2019-2030) & (K Units)
 Figure 17. Global KRAS Inhibitor Average Price (US$/Unit) & (2019-2030)
 Figure 18. KRAS Inhibitor Report Years Considered
 Figure 19. KRAS Inhibitor Sales Share by Manufacturers in 2023
 Figure 20. Global KRAS Inhibitor Revenue Share by Manufacturers in 2023
 Figure 21. Global 5 and 10 Largest KRAS Inhibitor Players: Market Share by Revenue in KRAS Inhibitor in 2023
 Figure 22. KRAS Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 23. Global KRAS Inhibitor Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 24. North America KRAS Inhibitor Sales Market Share by Country (2019-2030)
 Figure 25. North America KRAS Inhibitor Revenue Market Share by Country (2019-2030)
 Figure 26. United States KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 27. Canada KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 28. Europe KRAS Inhibitor Sales Market Share by Country (2019-2030)
 Figure 29. Europe KRAS Inhibitor Revenue Market Share by Country (2019-2030)
 Figure 30. Germany KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. France KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. U.K. KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 33. Italy KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 34. Russia KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 35. Asia Pacific KRAS Inhibitor Sales Market Share by Region (2019-2030)
 Figure 36. Asia Pacific KRAS Inhibitor Revenue Market Share by Region (2019-2030)
 Figure 37. China KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. Japan KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. South Korea KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. India KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. Australia KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 42. China Taiwan KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. Southeast Asia KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. Latin America KRAS Inhibitor Sales Market Share by Country (2019-2030)
 Figure 45. Mexico KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Brazil KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 47. Argentina KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 48. Colombia KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 49. Middle East and Africa KRAS Inhibitor Sales Market Share by Country (2019-2030)
 Figure 50. Middle East and Africa KRAS Inhibitor Revenue Market Share by Country (2019-2030)
 Figure 51. Turkey KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 52. Saudi Arabia KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 53. UAE KRAS Inhibitor Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 54. Global Sales Market Share of KRAS Inhibitor by Type (2019-2030)
 Figure 55. Global Revenue Market Share of KRAS Inhibitor by Type (2019-2030)
 Figure 56. Global KRAS Inhibitor Price (US$/Unit) by Type (2019-2030)
 Figure 57. Global Sales Market Share of KRAS Inhibitor by Application (2019-2030)
 Figure 58. Global Revenue Market Share of KRAS Inhibitor by Application (2019-2030)
 Figure 59. Global KRAS Inhibitor Price (US$/Unit) by Application (2019-2030)
 Figure 60. KRAS Inhibitor Value Chain
 Figure 61. KRAS Inhibitor Production Process
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Novocure